Table 3.

Population data for rifampicin model development in the diseased population.

No.	Population	No. of Subjects	Dose	Route	Age (Years)	Weight (kg)	Female Proportion	Reference Study
1	Tuberculosis	24	10 mg/kg	Oral	18–65		0.6	[15]
2	Tuberculosis	23	600 mg	Oral	18–55	Mean: 47	0.47	[50]
3	Tuberculosis	24	450 mg	Oral	18–55	Mean: 47	0.47	[50]
4	Tuberculosis	18	450 mg	Oral	18–60	47.3	0.61	[51]
5	Tuberculosis	13	450 mg	Oral	15–59		0	[37]
6	Tuberculosis	20	450 mg	Oral	Mean: 40.5	Mean: 42.9	0.4	[52]
7	Liver cirrhosis	7	4 mg/kg	Oral	18–60			[53]
8	Liver cirrhosis	7	6 mg/kg	Oral	18–60			[53]
9	Liver cirrhosis	7	8 mg/kg	Oral	18–60			[53]
10	Liver cirrhosis	7	10 mg/kg	oral	18–60			[53]